Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Трансдермальная контрацептивная система ЕВРА
Трансдермальная контрацептивная система ЕВРА
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Zieman M, Guillebaud J, Weisberg E et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77 (Suppl. 2): 813–8.
2. Archer D, Bigrigg A, Smallwood G et al. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American Women. Fertil Steril 2002; 77 (Suppl. 2): S27–31.
3. Smallwood G, Meador M, Lenihan JrJ et al. For the ORTHO EVRA/EVRA 002 Study Group. Efficacy and safety of a transdermal contraceptive system. Obstet Gyneco 2001; 98: 799–805.
4. Audet M-C, Moreau M, Koltun W et al. For the ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive. JAMA 2001; 285: 2347–54.
5. Archer D, Bigrigg A, Smallwood G et al. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American Women. Fertil Steril 2002; 77(Suppl. 2): S27–31.
6. Smallwood G, Meador M, Leruhan JrJ et al. For the ORTHO EVRA/EVRA 002 Study Group. Efficacy and safety of a transdermal contraceptive system. Obstet Gyneco 2001; 98: 799–805.
7. Audet M-C, Moreau M, Koltun W et al. For the ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive. JAMA 2001; 285: 2347–54.
7. Abrams L, Skee D, Natarajan J et al. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinylestradiol at four application sites. Br J Clin Pharmacol 2002b; 53: 141–6.
8. Rosenberg M, Waugh M. Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol 1999; 180: S276–9.
2. Archer D, Bigrigg A, Smallwood G et al. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American Women. Fertil Steril 2002; 77 (Suppl. 2): S27–31.
3. Smallwood G, Meador M, Lenihan JrJ et al. For the ORTHO EVRA/EVRA 002 Study Group. Efficacy and safety of a transdermal contraceptive system. Obstet Gyneco 2001; 98: 799–805.
4. Audet M-C, Moreau M, Koltun W et al. For the ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive. JAMA 2001; 285: 2347–54.
5. Archer D, Bigrigg A, Smallwood G et al. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American Women. Fertil Steril 2002; 77(Suppl. 2): S27–31.
6. Smallwood G, Meador M, Leruhan JrJ et al. For the ORTHO EVRA/EVRA 002 Study Group. Efficacy and safety of a transdermal contraceptive system. Obstet Gyneco 2001; 98: 799–805.
7. Audet M-C, Moreau M, Koltun W et al. For the ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive. JAMA 2001; 285: 2347–54.
7. Abrams L, Skee D, Natarajan J et al. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinylestradiol at four application sites. Br J Clin Pharmacol 2002b; 53: 141–6.
8. Rosenberg M, Waugh M. Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol 1999; 180: S276–9.
Авторы
В.Н.Прилепская, Н.М.Назарова, А.А.Куземин, В.В.Яглов
ГУ Научный центр акушерства, гинекологии и перинатологии
(дир. – акад. РАМН, проф. В.И.Кулаков) РАМН, Москва
ГУ Научный центр акушерства, гинекологии и перинатологии
(дир. – акад. РАМН, проф. В.И.Кулаков) РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.